Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

Dickran Kazandjian; Neha Korde; Sham Mailankody; Elizabeth Hill; William D. Figg; Mark Roschewski; Ola Landgren

doi:10.1001/jamaoncol.2018.5457

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

Dickran Kazandjian^*, Neha Korde, Sham Mailankody, Elizabeth Hill, William D. Figg, Mark Roschewski, Ola Landgren

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Letter › peer-review

38 Scopus citations

Original language	English
Pages (from-to)	1781-1783
Number of pages	3
Journal	JAMA Oncology
Volume	4
Issue number	12
DOIs	https://doi.org/10.1001/jamaoncol.2018.5457
State	Published - Dec 2018

Access to Document

10.1001/jamaoncol.2018.5457

Cite this

Kazandjian, D., Korde, N., Mailankody, S., Hill, E., Figg, W. D., Roschewski, M., & Landgren, O. (2018). Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. JAMA Oncology, 4(12), 1781-1783. https://doi.org/10.1001/jamaoncol.2018.5457

@article{11b7ca37187140508fe1b071820e7b3c,

title = "Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial",

author = "Dickran Kazandjian and Neha Korde and Sham Mailankody and Elizabeth Hill and Figg, {William D.} and Mark Roschewski and Ola Landgren",

note = "Funding Information: This work was supported by Memorial Sloan Kettering Core Grant P30CA008748 from the National Institutes of Health, National Cancer Institute (Drs Korde, Mailankody, and Landgren).",

year = "2018",

month = dec,

doi = "10.1001/jamaoncol.2018.5457",

language = "English",

volume = "4",

pages = "1781--1783",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "12",

}

Kazandjian, D, Korde, N, Mailankody, S, Hill, E, Figg, WD, Roschewski, M & Landgren, O 2018, 'Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial', JAMA Oncology, vol. 4, no. 12, pp. 1781-1783. https://doi.org/10.1001/jamaoncol.2018.5457

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. / Kazandjian, Dickran; Korde, Neha; Mailankody, Sham et al.
In: JAMA Oncology, Vol. 4, No. 12, 12.2018, p. 1781-1783.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone

T2 - Five-Year Follow-up of a Phase 2 Clinical Trial

AU - Kazandjian, Dickran

AU - Korde, Neha

AU - Mailankody, Sham

AU - Hill, Elizabeth

AU - Figg, William D.

AU - Roschewski, Mark

AU - Landgren, Ola

N1 - Funding Information: This work was supported by Memorial Sloan Kettering Core Grant P30CA008748 from the National Institutes of Health, National Cancer Institute (Drs Korde, Mailankody, and Landgren).

PY - 2018/12

Y1 - 2018/12

UR - http://www.scopus.com/inward/record.url?scp=85057080806&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.5457

DO - 10.1001/jamaoncol.2018.5457

M3 - Letter

C2 - 30477009

AN - SCOPUS:85057080806

SN - 2374-2437

VL - 4

SP - 1781

EP - 1783

JO - JAMA Oncology

JF - JAMA Oncology

IS - 12

ER -

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

Access to Document

Fingerprint

Cite this